Rapid Micro Biosystems shares surge 15.11% after-hours on multi-system order from major pharmaceutical client.

Rapid Micro Biosystems surged 15.11% in after-hours trading following a presentation at the Stifel 2025 Healthcare Conference. The company highlighted its GrowthDirect platform’s advancements in automating microbial quality control, securing a multi-system order from a major pharmaceutical client expected to boost Q4 2025 revenue. Strategic partnerships, including a collaboration with Merck-MilliporeSigma, were emphasized as growth drivers, alongside a 20% annual revenue growth target. The presentation also underscored five consecutive quarters of positive gross margins and operational efficiency gains, including faster validation times and expanded market reach. These developments reinforced investor confidence in the company’s ability to maintain its growth trajectory despite emerging competition.